Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriaan A van Bodegraven

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Alimentary Pharmacology & Therapeutics|September 28, 2023
Editorial: IBD cost evolution - transitioning from compensating lost productivity to escalating medication expensesAshkan Rezazadeh Ardabili, Adriaan A Van Bodegraven
Gastroenterology|January 29, 2014
Get the best out of thiopurine therapyNanne K H De Boer, Adriaan A Van Bodegraven
Current Opinion in Gastroenterology|December 17, 2020
Bone loss in patients with inflammatory bowel disease: cause, detection and treatmentNathalie Bravenboer, Angela E Oostlander, Adriaan A van Bodegraven
F1000 Medicine Reports|October 16, 2010
Diagnosing malabsorption in the intensive care unitMartijn B Keur, Albertus Beishuizen, Adriaan A van Bodegraven
Alimentary Pharmacology & Therapeutics|May 20, 2020
Editorial: the most commonly used IBD indices still fail to represent real life and subjective patient experienceRob H Creemers, Sjaak Bloem, Adriaan A van Bodegraven
Drugs of Today (Barcelona, Spain : 1998)|September 30, 2005
Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot studyOuafae Karimi, A Salvador Peña, Adriaan A van Bodegraven
Cancer Prevention Research (Philadelphia, Pa.)|March 1, 2013
Allopurinol in subjects with colorectal adenoma--letterNanne K H de Boer, Adriaan A van Bodegraven
Expert Opinion on Drug Metabolism & Toxicology|January 13, 2022
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel diseaseDebbie S Deben, Dennis R Wong, Adriaan A van Bodegraven
Journal of Crohn'S & Colitis|October 29, 2020
COVID-19 in the IBD Population: The Need for Correct NomenclatureAshkan Rezazadeh Ardabili, Rob H Creemers, Adriaan A van Bodegraven
Expert Opinion on Drug Metabolism & Toxicology|March 21, 2019
Key insights from therapeutic drug monitoring in Crohn's disease patientsMargien L Seinen, Nanne K De Boer, Adriaan A van Bodegraven
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Alimentary Pharmacology & Therapeutics|September 28, 2023
Editorial: IBD cost evolution - transitioning from compensating lost productivity to escalating medication expensesAshkan Rezazadeh Ardabili, Adriaan A Van Bodegraven
Gastroenterology|January 29, 2014
Get the best out of thiopurine therapyNanne K H De Boer, Adriaan A Van Bodegraven
Current Opinion in Gastroenterology|December 17, 2020
Bone loss in patients with inflammatory bowel disease: cause, detection and treatmentNathalie Bravenboer, Angela E Oostlander, Adriaan A van Bodegraven
F1000 Medicine Reports|October 16, 2010
Diagnosing malabsorption in the intensive care unitMartijn B Keur, Albertus Beishuizen, Adriaan A van Bodegraven
Alimentary Pharmacology & Therapeutics|May 20, 2020
Editorial: the most commonly used IBD indices still fail to represent real life and subjective patient experienceRob H Creemers, Sjaak Bloem, Adriaan A van Bodegraven
Drugs of Today (Barcelona, Spain : 1998)|September 30, 2005
Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot studyOuafae Karimi, A Salvador Peña, Adriaan A van Bodegraven
Cancer Prevention Research (Philadelphia, Pa.)|March 1, 2013
Allopurinol in subjects with colorectal adenoma--letterNanne K H de Boer, Adriaan A van Bodegraven
Expert Opinion on Drug Metabolism & Toxicology|January 13, 2022
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel diseaseDebbie S Deben, Dennis R Wong, Adriaan A van Bodegraven
Journal of Crohn'S & Colitis|October 29, 2020
COVID-19 in the IBD Population: The Need for Correct NomenclatureAshkan Rezazadeh Ardabili, Rob H Creemers, Adriaan A van Bodegraven
Expert Opinion on Drug Metabolism & Toxicology|March 21, 2019
Key insights from therapeutic drug monitoring in Crohn's disease patientsMargien L Seinen, Nanne K De Boer, Adriaan A van Bodegraven
Pageof 11